1. Membrane Transporter/Ion Channel
    Neuronal Signaling
  2. nAChR
  3. Sofiniclin

Sofiniclin (Synonyms: ABT 894)

Cat. No.: HY-14824 Purity: 95.98%
Handling Instructions

Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD).

For research use only. We do not sell to patients.

Sofiniclin Chemical Structure

Sofiniclin Chemical Structure

CAS No. : 799279-80-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 1160 In-stock
Estimated Time of Arrival: December 31
1 mg USD 432 In-stock
Estimated Time of Arrival: December 31
5 mg USD 864 Get quote
10 mg USD 1596 Get quote
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD)[1][2].

In Vitro

Sofiniclin is more potent than ABT-089 at both receptor subtypes, with Ki values of 1.9 nM for 125I-α-conotoxinMII binding and of 1.3 nM for 125I-epibatidine binding[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs compared to vehicle monkey[1]. Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight

244.12

Formula

C₁₀H₁₁Cl₂N₃

CAS No.

799279-80-4

SMILES

ClC1=C(Cl)C=C(N2C[[email protected]]3([H])CN[[email protected]]3([H])C2)C=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 7.35 mg/mL (30.11 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0963 mL 20.4817 mL 40.9635 mL
5 mM 0.8193 mL 4.0963 mL 8.1927 mL
10 mM 0.4096 mL 2.0482 mL 4.0963 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Kinase Assay

Receptor studies with ABT-089 and Sofiniclin are done using rat striatal sections. α6β2* nAChR levels are assayed using 125I-α-conotoxinMII (α-CtxMII) (specific activity, 2200 Ci/mmol). α4β2* nAChRs are measured by determining the binding of 125I-epibatidine (specific activity, 2200 Ci/mmol) in the presence of 100 nM α-CtxMII to block α6β2* nAChRs. After assay, sections are exposed to Kodak MR film. To evaluate binding, optical density readings are converted fmol/mg tissue using 125I-standards.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Monkeys: Once stable dyskinesias develops, the effects of ABT-089 and Sofiniclin are determined on LIDs. For these studies, there are two sets of MPTP-lesioned monkeys, Set A (n = 17) and Set B (n = 16). Set A monkeys have previously been treated with nicotine and/or nAChR drugs, followed by a 10 week ishout period (nAChR drug-primed). Set B monkeys have not received any nAChR drug when ABT-089 treatment is initiated (nAChR drug-naive). Our rationale for the use of these two sets of monkeys is to determine if prior treatment with nAChR drugs altered their ability to decrease LIDs. For both sets, there are 3 experimental groups of monkeys, a vehicle-treated group (n = 6), a nAChR drug-treated group (n = 5 or 6) and a nicotine-treated group (n = 5), as a positive control. The monkeys are assigned to the groups such that there are similar number of males and females, with comparable average LID scores.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Purity: 95.98%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

SofiniclinABT 894ABT894ABT-894nAChRNicotinic acetylcholine receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sofiniclin
Cat. No.:
HY-14824
Quantity:
MCE Japan Authorized Agent: